| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Taxifolin 7-rhamnoside targets bacterial cells, particularly MRSA, through mechanisms that result in antibacterial activity. As a flavonoid, it may exert its effects through multiple mechanisms including disruption of bacterial cell membranes, inhibition of bacterial enzymes, or interference with bacterial metabolism. The rhamnoside moiety may contribute to its specific activity and selectivity. Its antibacterial activity against clinical isolates of MRSA suggests potential for studying antibiotic resistance mechanisms and developing new antibacterial agents. The compound's flavonoid structure is characteristic of many plant-derived antibacterial compounds.
|
|---|---|
| ln Vitro |
In vitro, Taxifolin 7-rhamnoside has demonstrated antibacterial activity against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA). The compound's activity is typically assessed using standard antimicrobial susceptibility testing methods. As a flavonoid glycoside, it may also exhibit antioxidant and anti-inflammatory activities, although these are less extensively documented for this specific compound. Its antibacterial activity against MRSA makes it a compound of interest for studying drug-resistant bacterial infections. The compound's in vitro activity is concentration-dependent, with effective concentrations determined by MIC assays.
|
| ln Vivo |
In vivo studies of Taxifolin 7-rhamnoside are not extensively documented. As a compound with antibacterial activity against MRSA, it may have potential for studying infection models. However, comprehensive in vivo efficacy and safety data are limited. The compound is primarily used in in vitro research on antibacterial agents and natural product chemistry. Its flavonoid structure suggests potential for antioxidant and anti-inflammatory effects that could be explored in animal models. Further research is needed to fully characterize its in vivo biological activity and therapeutic potential. The compound is intended for research use only and not for human therapeutic applications.
|
| Enzyme Assay |
For in vitro biochemical assays, Taxifolin 7-rhamnoside is evaluated for its antibacterial activity. Minimum inhibitory concentration (MIC) is determined using broth microdilution or agar dilution methods against bacterial strains, including MRSA clinical isolates. The compound's purity and identity are confirmed by HPLC, NMR, and MS. Antioxidant activity can be assessed using DPPH, ABTS, or FRAP assays. Enzyme inhibition studies can be performed to evaluate effects on bacterial targets. These cell-free and cell-based assays help characterize the compound's antibacterial activity and mechanism of action.
|
| Cell Assay |
In vitro cellular assays for Taxifolin 7-rhamnoside are performed using bacterial cultures. Bacteria including MRSA clinical isolates are cultured in appropriate media and treated with the compound at various concentrations. Bacterial growth is monitored by measuring optical density or by colony counting. Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) are determined. For mechanistic studies, bacterial membrane integrity can be assessed using fluorescent dyes or by measuring leakage of cellular contents. Bacterial enzyme activities can be measured to identify specific targets. Cytotoxicity against mammalian cells is assessed to determine selectivity. These cellular assays help validate the compound's antibacterial activity and characterize its mechanism of action.
|
| Animal Protocol |
In vivo animal experiments with Taxifolin 7-rhamnoside are limited, as the compound is primarily used as a research tool for antibacterial studies. If used in animal studies, typical approaches would involve administration via oral gavage, intraperitoneal injection, or topical application. Infection models using MRSA or other bacteria could be used to assess antibacterial efficacy. Efficacy endpoints would include bacterial load reduction in infected tissues and survival. The compound's safety and tolerability would be monitored through body weight, clinical signs, and histopathology. Researchers should consult the primary literature for any available in vivo data.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Taxifolin 7-rhamnoside have been partially characterized. The compound has a molecular weight of 450.39 and is soluble in DMSO (100 mg/mL). For oral administration in vivo, it can be prepared as a homogeneous suspension in CMC-Na at ≥5 mg/mL. As a flavonoid glycoside, it is expected to have moderate oral bioavailability. The compound may be hydrolyzed by intestinal enzymes to release the aglycone. Detailed PK parameters such as half-life, Cmax, Tmax, AUC, and protein binding are not extensively documented. The compound should be stored under recommended conditions to maintain stability.
|
| Toxicity/Toxicokinetics |
The toxicological profile of Taxifolin 7-rhamnoside is not extensively characterized. As a natural flavonoid from Hypericum japonicum, it is generally considered to have a favorable safety profile, but comprehensive toxicity studies are limited. The compound is intended for research use only and not for human therapeutic applications. Its effects at high concentrations and potential interactions with other drugs or compounds have not been fully investigated. Researchers should follow standard laboratory safety practices when handling Taxifolin 7-rhamnoside. The compound's antibacterial activity suggests selectivity for bacterial over mammalian cells, but cytotoxicity should be assessed for specific applications.
|
| Additional Infomation |
According to reports, Hypericum japonicum contains taxonomic 7-O-rhamnoside, and there is relevant data.
Taxifolin 7-rhamnoside is a valuable research tool for studying antibacterial agents, particularly against methicillin-resistant Staphylococcus aureus (MRSA). Its activity against clinical isolates of MRSA makes it useful for investigating antibiotic resistance mechanisms and developing new strategies to combat drug-resistant bacterial infections. The compound is also relevant for natural product chemistry research as a flavonoid glycoside from Hypericum japonicum. Its structure makes it an interesting model for studying structure-activity relationships in flavonoid antibacterial agents. Taxifolin 7-rhamnoside can be employed in studies on bacterial membrane disruption, enzyme inhibition, and the development of combination therapies for resistant infections. |
| Molecular Formula |
C21H22O11
|
|---|---|
| Molecular Weight |
450.3928
|
| Exact Mass |
450.116
|
| CAS # |
137592-12-2
|
| PubChem CID |
24721355
|
| Appearance |
Off-white to light yellow solid
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
832.5±65.0 °C at 760 mmHg
|
| Flash Point |
293.9±27.8 °C
|
| Vapour Pressure |
0.0±3.2 mmHg at 25°C
|
| Index of Refraction |
1.719
|
| LogP |
1.14
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
32
|
| Complexity |
676
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
O1[C@]([H])([C@@]([H])([C@@]([H])([C@]([H])([C@]1([H])C([H])([H])[H])O[H])O[H])O[H])OC1=C([H])C(=C2C([C@@]([H])([C@@]([H])(C3C([H])=C([H])C(=C(C=3[H])O[H])O[H])OC2=C1[H])O[H])=O)O[H]
|
| InChi Key |
HNGAZJABJOAMSW-FHXNIQKESA-N
|
| InChi Code |
InChI=1S/C21H22O11/c1-7-15(25)17(27)19(29)21(30-7)31-9-5-12(24)14-13(6-9)32-20(18(28)16(14)26)8-2-3-10(22)11(23)4-8/h2-7,15,17-25,27-29H,1H3/t7-,15-,17+,18-,19+,20+,21-/m0/s1
|
| Chemical Name |
(2R,3R)-2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-2,3-dihydrochromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~70 mg/mL (~155.42 mM)
H2O : ~14.29 mg/mL (~31.73 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.62 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.62 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.62 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2203 mL | 11.1015 mL | 22.2030 mL | |
| 5 mM | 0.4441 mL | 2.2203 mL | 4.4406 mL | |
| 10 mM | 0.2220 mL | 1.1101 mL | 2.2203 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
